Share Email Print
cover

Proceedings Paper

Excimer laser debridement of necrotic erosions of skin without collateral damage
Author(s): James J. Wynne; Jerome M. Felsenstein; Robert Trzcinski; Donna Zupanski-Nielsen; Daniel P. Connors
Format Member Price Non-Member Price
PDF $17.00 $21.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Pulsed ArF excimer laser radiation at 6.4 eV, at fluence exceeding the ablation threshold, will debride burn eschar and other dry necrotic erosions of the skin. Debridement will cease when sufficiently moist viable tissue is exposed, due to absorption by aqueous chloride ions (Cl-) through the non-thermal process of electron photodetachment, thereby inhibiting collateral damage to the viable tissue. ArF excimer laser radiation debrides/ablates ~1 micron of tissue with each pulse. While this provides great precision in controlling the depth of debridement, the process is relatively time-consuming. In contrast, XeCl excimer laser radiation debrides ~8 microns of tissue with each pulse. However the 4.0 eV photon energy of the XeCl excimer laser is insufficient to photodetach an electron from a Cl- ion, so blood or saline will not inhibit debridement. Consequently, a practical laser debridement system should incorporate both lasers, used in sequence. First, the XeCl excimer laser would be used for accelerated debridement. When the necrotic tissue is thinned to a predetermined thickness, the ArF excimer laser would be used for very precise and well-controlled debridement, removing ultra-thin layers of material with each pulse. Clearly, the use of the ArF laser is very desirable when debriding very close to the interface between necrotic tissue and viable tissue, where the overall speed of debridement need not be so rapid and collateral damage to viable tissue is undesirable. Such tissue will be sterile and ready for further treatment, such as a wound dressing and/or a skin graft.

Paper Details

Date Published: 7 June 2011
PDF: 8 pages
Proc. SPIE 8092, Medical Laser Applications and Laser-Tissue Interactions V, 809213 (7 June 2011); doi: 10.1117/12.889741
Show Author Affiliations
James J. Wynne, IBM T. J. Watson Research Lab. (United States)
Jerome M. Felsenstein, Consultant (United States)
Robert Trzcinski, IBM T. J. Watson Research Lab. (United States)
Donna Zupanski-Nielsen, IBM T. J. Watson Research Lab. (United States)
Daniel P. Connors, IBM T. J. Watson Research Lab. (United States)


Published in SPIE Proceedings Vol. 8092:
Medical Laser Applications and Laser-Tissue Interactions V
Ronald Sroka; Lothar D. Lilge, Editor(s)

© SPIE. Terms of Use
Back to Top